BC Innovations | Jun 21, 2017
Distillery Techniques

Drug delivery

TECHNOLOGY: Polymers PEG-based hydrogel microspheres that release peptide drugs continuously over several weeks could help treat Type II diabetes and other chronic diseases with once-monthly dosing. The microspheres are linked to peptide therapeutics via a...
BioCentury | Jul 9, 2012
Strategy

Triple play in diabetes

The addition of Amylin Pharmaceuticals Inc. 's glucagon-like peptide 1 franchise will give partners Bristol-Myers Squibb Co. and AstraZeneca plc three modern mechanisms in their commercial diabetes portfolio and five in the pipeline - more than...
BC Week In Review | Jul 4, 2011
Clinical News

Exenatide once monthly: Additional Phase II data

Additional data from an open-label, U.S. Phase II trial in 121 Type II diabetics showed that 50%, 57% and 70% of patients receiving 5, 8 and 11 mg subcutaneous exenatide once monthly, respectively, achieved an...
BC Week In Review | Mar 14, 2011
Clinical News

Exenatide once monthly: Phase II data

An open-label, U.S. Phase II trial in 121 Type II diabetics showed that low-, mid- and high-dose subcutaneous exenatide once monthly reduced mean HbA1c from baseline to week 20 by 1.3-1.5% vs. 1.5% for 2...
BioCentury | Mar 14, 2011
Finance

Still some pop in Benlysta

Human Genome Sciences Inc. (NASDAQ:HGSI) gained $446 million in market cap last week on the approval of Benlysta belimumab, benefitting from a better label and pricing than investors had expected. The approval was announced post-market...
BioCentury | Mar 14, 2011
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Elan Corp. plc (NYSE:ELN) was up $0.03 to $6.56 last week after the European Commission approved an MAA for Xeplion paliperidone palmitate from Johnson & Johnson (NYSE:JNJ) for the maintenance treatment of schizophrenia...
BC Extra | Mar 11, 2011
Clinical News

Amylin, partners report exenatide once monthly data

Alkermes Inc. (NASDAQ:ALKS), Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) and Eli Lilly and Co. (NYSE:LLY) said low-, mid- and high-doses of exenatide once monthly reduced mean HbA1c from baseline to week 20 by 1.3-1.5% vs. 1.5% for...
BioCentury | Oct 25, 2010
Regulation

Haunted by Byetta

Instead of a relatively small QTc study, Amylin Pharmaceuticals Inc. and Eli Lilly and Co. took a different tack - initially with FDA's blessing - that now looks likely to cost the partners at least 18 months...
Items per page:
1 - 8 of 8